8-K
VIEMED HEALTHCARE, INC. (VMD)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2026
Viemed Healthcare, Inc.
(Exact name of registrant as specified in its charter)
| British Columbia, Canada | 001-38973 | N/A | |||
|---|---|---|---|---|---|
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) | 625 E. Kaliste Saloom Rd.<br><br>Lafayette, Louisiana | 70508 | |
| --- | --- | ||||
| (Address of principal executive offices) | (Zip Code) |
(337) 504-3802
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | --- | --- || ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | --- | --- || ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | --- | --- || ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common shares, no par value | VMD | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 5, 2026, Viemed Healthcare, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In addition, the Company issued a Financial Supplement with respect to its financial results for the three months ended March 31, 2026. The Financial Supplement is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information, including Exhibits 99.1 and 99.2 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
|---|---|
| Exhibit <br>Number | Description |
| --- | --- |
99.1 Press Release dated May 5, 2026.
99.2 Financial Supplement dated May 5, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 5, 2026
| VIEMED HEALTHCARE, INC. | |
|---|---|
| By: | /s/ Trae Fitzgerald |
| Trae Fitzgerald | |
| Chief Financial Officer |
Document
VIEMED HEALTHCARE ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS
Lafayette, Louisiana (May 5, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three months ended March 31, 2026, and updated guidance for the full year ending December 31, 2026.
Operational highlights (all dollar amounts are USD):
•Net revenues for the quarter ended March 31, 2026 were $75.4 million, representing an increase of $16.3 million, or 28%, over net revenues reported for the comparable quarter ended March 31, 2025.
•Net income attributable to Viemed for the quarter ended March 31, 2026 totaled $2.6 million, or $0.06 per diluted share.
•Adjusted EBITDA for the quarter ended March 31, 2026 totaled $14.3 million, a 12% increase as compared to the quarter ended March 31, 2025. The prior year period benefited from a $2.7 million non-recurring gain on disposal of property and equipment related to the ventilator return program, which concluded during 2025.
•Net cash provided by operating activities totaled $8.1 million for the quarter and $57.1 million for the trailing twelve months ended March 31, 2026. Free cash flow totaled $2.6 million for the quarter and $36.3 million for the trailing twelve months ended March 31, 2026.
•During the first quarter of 2026, the Company repurchased and cancelled 150,000 common shares under its share repurchase program at a cost of $1.4 million (excluding taxes), representing an average buyback price of $9.29 per share.
•The Company's ventilator patient count totaled 12,089 as of March 31, 2026, an increase of 2% over March 31, 2025.
•The Company increased its PAP therapy patient count to 35,938 as of March 31, 2026, an increase of 57% over March 31, 2025, and a 4% sequential increase from December 31, 2025. The Company's sleep resupply patient count was 33,661 as of March 31, 2026, an increase of 47% over March 31, 2025, and an 8% sequential decrease from December 31, 2025.
•As of March 31, 2026, the Company maintained a cash balance of $9.8 million, and an overall working capital balance of $9.1 million. The Company repaid $3.2 million of its term loan during the quarter ended March 31, 2026. Long-term debt totaled $8.3 million and the Company had $46 million available under existing credit facilities.
Updated Full Year 2026 Guidance (all dollar amounts are USD):
The Company is updating its full-year 2026 guidance to reflect increased forecasting precision and favorable trends in new patient starts, which support a narrowing of the revenue range. The Company is also updating its net capital expenditure outlook to reflect the continued shift in revenue mix toward less capital-intensive service lines, which is producing a structurally lower level of capital intensity than originally anticipated. Adjusted EBITDA guidance is reaffirmed.
•Net revenue is now expected to be in the range of $312 million to $320 million, narrowed and raised from the prior range of $310 million to $320 million.
•Adjusted EBITDA is expected to be in the range of $65 million to $69 million.
•Net capital expenditures are now expected to be in the range of 9% to 10.5% of net revenue, updated from the prior range of 10% to 11.5%.
See “Use of Non-GAAP Financial Information and Financial Guidance” below for further information about non-GAAP financial measures and non-GAAP financial guidance.
Casey Hoyt, Viemed’s Chief Executive Officer, commented, "The first quarter showed clearly that the work we have put into diversifying and scaling this platform is paying off. Sleep and maternal health are growing rapidly, our ventilator business is showing the momentum we have been working toward, and the combination of strong revenue growth and a more capital-efficient business mix is producing free cash flow results that look fundamentally different than they did a year ago. We believe that trajectory will become an increasingly important part of how investors understand and value Viemed. We are executing the plan we communicated, the forward indicators across the business are pointing in the right direction, and we enter the second quarter with real confidence in where this year is headed."
Conference Call Details
The Company will host a conference call to discuss its first quarter results, as well as its 2026 guidance, on Wednesday, May 6, 2026, at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
877-407-6176 (US Toll-Free)
+1 201-689-8451 (International)
Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=MWjE55eM
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of home medical equipment and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. Viemed’s model emphasizes efficient, high-quality care delivered in the home through a combination of high-touch clinical support and technology-enabled services, including therapy, education, and counseling provided by our clinical practitioners. For more information, visit our website at www.viemed.com.
For further information, please contact:
Investor Relations
ir@viemed.com
Trae Fitzgerald
Chief Financial Officer
337-504-3802
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue, Adjusted EBITDA and capital expenditures guidance for 2026 and capital allocation priorities, including share repurchases and free cash flow generation, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; and the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
Use of Non-GAAP Financial Information and Financial Guidance
This press release includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company’s consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the tables accompanying this release.
This press release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. The Company’s financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except share amounts)
(Unaudited)
| At<br>March 31, 2026 | At<br>December 31, 2025 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | $ | 9,762 | $ | 13,501 |
| Accounts receivable, net | 31,179 | 25,586 | ||
| Inventory | 5,183 | 5,047 | ||
| Income tax receivable | — | 227 | ||
| Prepaid expenses and other assets | 3,687 | 4,132 | ||
| Total current assets | $ | 49,811 | $ | 48,493 |
| Long-term assets | ||||
| Property and equipment, net | 76,007 | 78,775 | ||
| Operating lease right-of-use assets | 3,301 | 3,580 | ||
| Equity investments | 2,794 | 2,794 | ||
| Deferred tax asset | 5,289 | 5,289 | ||
| Identifiable intangibles, net | 1,221 | 1,285 | ||
| Goodwill | 58,938 | 58,938 | ||
| Total long-term assets | $ | 147,550 | $ | 150,661 |
| TOTAL ASSETS | $ | 197,361 | $ | 199,154 |
| LIABILITIES | ||||
| Current liabilities | ||||
| Trade payables | $ | 8,575 | $ | 7,333 |
| Deferred revenue | 7,479 | 7,520 | ||
| Income taxes payable | 1,038 | — | ||
| Accrued liabilities | 21,542 | 23,910 | ||
| Operating lease liabilities, current portion | 1,201 | 1,203 | ||
| Current portion of long-term debt | 871 | 1,090 | ||
| Total current liabilities | $ | 40,706 | $ | 41,056 |
| Long-term liabilities | ||||
| Accrued liabilities | 494 | 922 | ||
| Operating lease liabilities, less current portion | 2,031 | 2,364 | ||
| Long-term debt | 8,334 | 11,291 | ||
| Total long-term liabilities | $ | 10,859 | $ | 14,577 |
| TOTAL LIABILITIES | $ | 51,565 | $ | 55,633 |
| Commitments and Contingencies | — | — | ||
| SHAREHOLDERS' EQUITY | ||||
| Common stock - No par value: unlimited authorized; 38,533,586 and 38,019,082 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 20,811 | 16,912 | ||
| Additional paid-in capital | 17,579 | 21,742 | ||
| Retained Earnings | 105,473 | 102,891 | ||
| TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | $ | 143,863 | $ | 141,545 |
| Noncontrolling interest in subsidiary | 1,933 | 1,976 | ||
| TOTAL SHAREHOLDERS' EQUITY | $ | 145,796 | $ | 143,521 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 197,361 | $ | 199,154 |
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
(Unaudited)
| Three Months Ended March 31, | ||||
|---|---|---|---|---|
| 2026 | 2025 | |||
| Revenue | $ | 75,414 | $ | 59,129 |
| Cost of revenue | 32,587 | 25,850 | ||
| Gross profit | $ | 42,827 | $ | 33,279 |
| Operating expenses | ||||
| Selling, general and administrative | 34,792 | 28,425 | ||
| Research and development | 579 | 797 | ||
| Stock-based compensation | 2,451 | 2,311 | ||
| Depreciation and amortization | 388 | 348 | ||
| Loss (gain) on disposal of property and equipment | 356 | (2,368) | ||
| Other income, net | (35) | (75) | ||
| Income from operations | $ | 4,296 | $ | 3,841 |
| Non-operating income and expenses | ||||
| Interest expense, net | 305 | 179 | ||
| Net income before taxes | 3,991 | 3,662 | ||
| Provision for income taxes | 1,278 | 952 | ||
| Net income | $ | 2,713 | $ | 2,710 |
| Net income attributable to noncontrolling interest | 131 | 85 | ||
| Net income attributable to Viemed Healthcare, Inc. | $ | 2,582 | $ | 2,625 |
| Net income per share | ||||
| Basic | $ | 0.07 | $ | 0.07 |
| Diluted | $ | 0.06 | $ | 0.06 |
| Weighted average number of common shares outstanding: | ||||
| Basic | 38,428,588 | 39,426,753 | ||
| Diluted | 40,491,298 | 41,627,876 |
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)
| Three Months Ended March 31, | ||||
|---|---|---|---|---|
| 2026 | 2025 | |||
| Cash flows from operating activities | ||||
| Net income | $ | 2,713 | $ | 2,710 |
| Adjustments for: | ||||
| Depreciation and amortization | 7,621 | 6,613 | ||
| Stock-based compensation expense | 2,451 | 2,311 | ||
| Loss (gain) on disposal of property and equipment | 356 | (2,368) | ||
| Amortization of deferred financing costs | 66 | 35 | ||
| Changes in working capital: | ||||
| Accounts receivable, net | (5,593) | (1,878) | ||
| Inventory | (136) | (190) | ||
| Prepaid expenses and other assets | 389 | (601) | ||
| Trade payables | 1,582 | 1,176 | ||
| Deferred revenue | (41) | 101 | ||
| Accrued liabilities | (2,602) | (3,050) | ||
| Income tax payable/receivable | 1,265 | (2,005) | ||
| Net cash provided by operating activities | $ | 8,071 | $ | 2,854 |
| Cash flows from investing activities | ||||
| Purchase of property and equipment | (6,712) | (15,483) | ||
| Proceeds from sale of property and equipment | 1,227 | 6,953 | ||
| Net cash used in investing activities | $ | (5,485) | $ | (8,530) |
| Cash flows from financing activities | ||||
| Proceeds from exercise of options | 526 | 11 | ||
| Principal payments on term notes | (3,242) | (113) | ||
| Shares redeemed to pay income tax | (1,996) | (1,584) | ||
| Payments for share repurchase programs | (1,439) | — | ||
| Repayments of finance lease liabilities | — | (18) | ||
| Distributions to non-controlling interest | (174) | — | ||
| Net cash used in financing activities | $ | (6,325) | $ | (1,704) |
| Net decrease in cash and cash equivalents | (3,739) | (7,380) | ||
| Cash and cash equivalents at beginning of year | 13,501 | 17,540 | ||
| Cash and cash equivalents at end of period | $ | 9,762 | $ | 10,160 |
| Supplemental disclosures of cash flow information | ||||
| Cash paid during the period for interest | $ | 226 | $ | 125 |
| Cash paid during the period for income taxes, net of refunds | $ | 14 | $ | 2,957 |
| Supplemental disclosures of non-cash transactions | ||||
| Equipment and other fixed asset purchases payable at end of period | $ | 2,881 | $ | 3,625 |
| Equipment sales receivable at end of period | $ | — | $ | 3,832 |
Reconciliation from GAAP Net Income to Non-GAAP Adjusted EBITDA
This press release refers to “Adjusted EBITDA”, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. Adjusted EBITDA is not a measurement of the Company’s financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income attributable to Viemed Healthcare, Inc., including depreciation and amortization of capitalized assets, net interest expense, stock based compensation, transaction costs, impairment of assets, and taxes.
The following unaudited table is a reconciliation of net income attributable to Viemed Healthcare, Inc., the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
(Expressed in thousands of U.S. Dollars)
| For the quarter ended | March 31, 2026 | December 31, 2025 | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income attributable to Viemed Healthcare, Inc. | $ | 2,582 | $ | 5,639 | $ | 3,513 | $ | 3,157 | $ | 2,625 | $ | 4,316 | $ | 3,878 | $ | 1,468 |
| Add back: | ||||||||||||||||
| Depreciation & amortization | 7,621 | 7,570 | 7,539 | 6,891 | 6,613 | 6,366 | 6,408 | 6,309 | ||||||||
| Interest expense, net | 305 | 364 | 507 | 132 | 179 | 147 | 225 | 254 | ||||||||
| Stock-based compensation(a) | 2,451 | 2,300 | 2,180 | 2,341 | 2,311 | 1,521 | 1,712 | 1,620 | ||||||||
| Transaction costs(b) | 74 | 139 | 847 | 53 | 85 | 11 | 12 | 221 | ||||||||
| Impairment of assets(c) | — | — | — | — | — | — | 125 | 2,173 | ||||||||
| Income tax expense | 1,278 | 2,191 | 1,535 | 1,713 | 952 | 1,881 | 1,594 | 768 | ||||||||
| Adjusted EBITDA | $ | 14,311 | $ | 18,203 | $ | 16,121 | $ | 14,287 | $ | 12,765 | $ | 14,242 | $ | 13,954 | $ | 12,813 |
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(c) Represents impairments of the fair value of investment and litigation-related assets.
Reconciliation from GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow
This press release refers to “free cash flow” which is a non-GAAP financial measure that does not have a standardized meaning prescribed by GAAP. Free cash flow is defined as net cash provided by operating activities less net capital expenditures (“Net CAPEX”). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies.
The Company presents free cash flow for the current quarter and trailing twelve months (TTM) as a supplemental liquidity measure. Management believes free cash flow provides investors with useful insight into the Company’s ability to generate cash, fund growth initiatives, and return capital to shareholders.
The following table is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP measure, to free cash flow, on a historical basis for the periods indicated:
(Expressed in thousands of U.S. Dollars; unaudited)
| TTM | For the quarter ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | March 31, 2026 | December 31, 2025 | September 30, 2025 | June 30, 2025 | ||||||
| Net cash provided by operating activities | $ | 57,133 | $ | 8,071 | $ | 18,441 | $ | 18,367 | $ | 12,254 |
| Less: | ||||||||||
| Purchase of property and equipment | (31,214) | (6,712) | (8,737) | (7,636) | (8,129) | |||||
| Proceeds from sale of property and equipment | 10,425 | 1,227 | 1,125 | 1,671 | 6,402 | |||||
| Net CAPEX | (20,789) | (5,485) | (7,612) | (5,965) | (1,727) | |||||
| Free cash flow | $ | 36,344 | $ | 2,586 | $ | 10,829 | $ | 12,402 | $ | 10,527 |
viemed_q12026supplementa
1 Financial Supplement First Quarter 2026 May 5, 2026 NASDAQ: VMD
Disclaimers Forward Looking Statements Certain statements contained in this Financial Supplement may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue, Adjusted EBITDA and capital expenditures guidance for 2026 and capital allocation priorities, including share repurchases, liquidity position, free cash flow generation, and strategic growth opportunities, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward- looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, claims resulting from such events or concerns; the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this Financial Supplement are made as of the date of this Financial Supplement and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. This Financial Supplement contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. The Company’s financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above. Non-GAAP and Other Financial Information This presentation includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company’s consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. Reconciliations between GAAP and non-GAAP financial information are provided within this financial supplement. 2 VieMed Healthcare Inc. I Supplemental Presentation
Key Themes for Q1 2026 3 Strong revenue growth across core services, including continued diversification in sleep and maternal health, combined with a more capital-efficient business mix, drove durable free cash flow generation and supported capital return and deleveraging • Revenue increased 28% year-over-year • Sleep platform momentum remained strong, with patients up 57% year-over-year and new patient starts up 42%, supporting growth visibility • Ventilator patient growth remained stable at 2% year-over-year • Adjusted EBITDA grew 12% year-over-year to $14.3M, with the prior year period benefiting from a $2.7M non-recurring gain related to the ventilator return program. • Generated $8.1 million of operating cash flow and $2.6 million of free cash flow • Repurchased 150,000 shares for $1.4 million and reduced debt through $3.2 million of term loan repayments, continuing disciplined capital allocation VieMed Healthcare Inc. I Supplemental Presentation
Financial and Operational Highlights 4 (expressed in thousands of U.S. Dollars, except operational information). (1) Refer to “Adjusted EBITDA" in this presentation for the definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure. (2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter. (3) PAP Therapy Patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter. (4) Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter. For the quarter ended: 3/31/26 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 Financial Information: Revenue $75,414 $76,181 $71,914 $63,056 $59,129 $60,695 $58,004 $54,965 Gross Profit $42,827 $44,103 $41,345 $36,731 $33,279 $36,138 $34,371 $32,892 Gross Profit % 57% 58% 57% 58% 56% 60% 59% 60% Net Income attributable to Viemed Healthcare, Inc. $2,582 $5,639 $3,513 $3,157 $2,625 $4,316 $3,878 $1,468 Cash and Cash Equivalents (As of) $9,762 $13,501 $11,123 $20,016 $10,160 $17,540 $11,347 $8,807 Total Assets (As of) $197,361 $199,154 $202,360 $184,603 $178,079 $177,069 $169,526 $163,947 Adjusted EBITDA(1) $14,311 $18,203 $16,121 $14,287 $12,765 $14,242 $13,954 $12,813 Operational Information: Vent Patients(2) 12,089 12,259 12,372 12,152 11,809 11,795 11,374 10,905 PAP Therapy Patients(3) 35,938 34,528 31,891 26,260 22,899 21,338 19,478 17,349 Sleep Resupply Patients(4) 33,661 36,561 33,518 25,246 22,941 24,478 22,143 20,185 VieMed Healthcare Inc. I Supplemental Presentation
Medicare 41% Medicaid/ MCO 8% Medicare Advantage 21% Commercial 17% Other 13% Medicare 35% Medicaid/ MCO 10% Medicare Advantage 20% Commercial 23% Other 12% Ventilation 47% Oxygen 8% Sleep 20% Airway Clearance 7% Maternal 8% Staffing 8% Other 2% Q1 2026 Rental 68% Sales 32% Ventilation 54% Oxygen 10% Sleep 16% Airway Clearance 7% Staffing 10% Other 3% Q1 2025 Service, Payor and Revenue Mix 5 SERVICE MIX PAYOR MIX REVENUE MIX VieMed Healthcare Inc. I Supplemental Presentation SERVICE MIX PAYOR MIX Rental 76% Sales 24% REVENUE MIX
Revenue Highlights 6 For the quarter ended 3/31/26 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 Rental Revenue (expressed in thousands of USD): Ventilators, non-invasive & invasive $35,360 $35,888 $34,883 $33,819 $32,159 $33,173 $31,772 $30,445 Other home medical equipment rentals $16,198 $16,200 $15,401 $13,823 $12,962 $13,047 $12,459 $12,211 Sales & Service Revenue (expressed in thousands of USD): Equipment and supply sales $17,488 $17,521 $15,700 $9,514 $7,519 $8,940 $8,440 $7,378 Service revenues $6,368 $6,572 $5,930 $5,900 $6,489 $5,535 $5,333 $4,931 Total revenues $75,414 $76,181 $71,914 $63,056 $59,129 $60,695 $58,004 $54,965 Rental Revenue (% of Total revenue): Ventilators, non-invasive & invasive 46.9% 47.1% 48.5% 53.6% 54.4% 54.7% 54.8% 55.4% Other home medical equipment rentals 21.5% 21.3% 21.4% 21.9% 21.9% 21.5% 21.5% 22.2% Sales & Service Revenue (% of Total revenue): Equipment and supply sales 23.2% 23.0% 21.8% 15.1% 12.7% 14.7% 14.6% 13.4% Service revenues 8.4% 8.6% 8.3% 9.4% 11.0% 9.1% 9.2% 9.0% Total revenues 100% 100% 100% 100% 100% 100% 100% 100% VieMed Healthcare Inc. I Supplemental Presentation
Liquidity Metrics 7 Positioned for growth • The Company maintains a healthy balance sheet with effectively no net debt as of March 31, 2026, providing significant financial flexibility. • As of March 31, 2026, the Company had $46 million in unfunded commitments available under its existing credit facilities, supporting our capital allocation strategy. For the period ended 3/31/26 12/31/25 12/31/24 Cash on hand $ 9,762 $ 13,501 $ 17,540 Working Capital $ 9,105 $ 7,437 $ 15,554 Long Term Debt $ 8,334 $ 11,291 $ 3,589 VieMed Healthcare Inc. I Supplemental Presentation (expressed in thousands of U.S. Dollars)
Free Cash Flow 8 TTM For the quarter ended 3/31/26 3/31/26 12/31/25 9/30/25 6/30/25 Net cash provided by operating activities $ 57,133 $ 8,071 $ 18,441 $ 18,367 $ 12,254 Less: Purchase of property and equipment (31,214) (6,712) (8,737) (7,636) (8,129) Proceeds from sale of property and equipment 10,425 1,227 1,125 1,671 6,402 Net CAPEX (20,789) (5,485) (7,612) (5,965) (1,727) Free cash flow $ 36,344 $ 2,586 $ 10,829 $ 12,402 $ 10,527 VieMed Healthcare Inc. I Supplemental Presentation (expressed in thousands of U.S. Dollars) Reconciliation from GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow We present non-GAAP free cash flow for the current quarter and trailing twelve months (TTM) as a supplemental liquidity measure. Management believes free cash flow provides investors with useful insight into the company’s ability to generate cash, fund growth initiatives, and return capital to shareholders. Free cash flow is defined as net cash provided by operating activities, as reported under U.S. GAAP, less net capital expenditures (Net CAPEX). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment in order to reflect both outflows and inflows associated with routine equipment turnover. Trailing twelve months (TTM) free cash flow is calculated by aggregating the last four quarters, each calculated using the methodology described above.
2026 Annual Guidance – Commentary 9 Core Metrics • Net revenue of $312 million to $320 million (narrowed and raised from $310 million to $320 million) • Adjusted EBITDA of $65 million to $69 million (reaffirmed) • Net capital expenditures of 9% to 10.5% of net revenue (updated from prior range of 10% to 11.5%) Q1 2026 Performance vs. Seasonal Guidance • Q1 revenue of $75.4 million was essentially flat compared to Q4 2025, consistent with the seasonal pattern described at the time of initial guidance • Sequential revenue growth of 3% to 5% per quarter expected in Q2, Q3, and Q4 Key Assumptions • Excludes the impact of potential acquisitions • Revenue range narrowed upward reflecting increased forecasting precision and favorable new patient start trends • Updated net CAPEX outlook reflects the continued shift toward less capital-intensive service lines VieMed Healthcare Inc. I Supplemental Presentation
Adjusted EBITDA 10 (a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impairments of the fair value of investment and litigation-related assets. Reconciliation of Net Income to Non-GAAP Adjusted EBITDA For the quarter ended: 3/31/26 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 Net Income attributable to Viemed Healthcare, Inc. $ 2,582 $ 5,639 $ 3,513 $ 3,157 $ 2,625 $ 4,316 $ 3,878 $ 1,468 Add back: Depreciation & amortization 7,621 7,570 7,539 6,891 6,613 6,366 6,408 6,309 Interest expense, net 305 364 507 132 179 147 225 254 Stock-based compensation(a) 2,451 2,300 2,180 2,341 2,311 1,521 1,712 1,620 Transaction costs(b) 74 139 847 53 85 11 12 221 Impairment of assets(c) - - - - - - 125 2,173 Income tax expense 1,278 2,191 1,535 1,713 952 1,881 1,594 768 Adjusted EBITDA $ 14,311 $ 18,203 $ 16,121 $ 14,287 $ 12,765 $ 14,242 $ 13,954 $ 12,813 VieMed Healthcare Inc. I Supplemental Presentation (expressed in thousands of U.S. Dollars) Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management.